8-K: Sanofi to Acquire Dynavax for $2.2 Billion

Sentiment:

Merger Announcement 29 December 2025 7:31 AM

📋All filings for Dynavax Technologies CORP

Sanofi announced an agreement to acquire Dynavax Technologies Corporation for $15.50 per share in cash, a 39% premium, adding a marketed adult hepatitis B vaccine and a shingles candidate to its portfolio.

Better than expectedDynavax stockholders are receiving a significant premium of 39% over the closing share price and 46% over the 3-month VWAP.The acquisition provides a clear exit strategy and immediate cash value for shareholders.The transaction is unanimously approved by the Dynavax board, indicating their belief it is in the best interest of the company and its stockholders.

Summary

Sanofi will acquire Dynavax Technologies Corporation for $15.50 per share in cash.
The total equity value of the transaction is approximately $2.2 billion.
The offer price represents a premium of approximately 39% over Dynavax's closing share price on December 23, 2025.
It also represents a premium of approximately 46% over the 3-month volume-weighted average price (VWAP) of Dynavax as of December 23, 2025.
The acquisition includes Dynavax's marketed adult hepatitis B vaccine, HEPLISAV-B, and its Phase 1/2 shingles vaccine candidate, Z-1018, along with additional vaccine pipeline projects.
The transaction has been unanimously approved by Dynavax's board of directors.
The acquisition is expected to close in the first quarter of 2026, subject to customary closing conditions including regulatory approvals and a majority tender of shares.

Sentiment

Score: 9

Explanation: The acquisition at a substantial premium for Dynavax shareholders, coupled with the strategic fit for Sanofi's adult immunization portfolio and the potential for pipeline amplification, indicates a highly positive outcome for Dynavax and its investors.

Positives

Dynavax stockholders receive a significant premium of 39% over the closing price and 46% over the 3-month VWAP.
HEPLISAV-B, a differentiated adult hepatitis B vaccine, gains Sanofi's global scale, development capabilities, and commercial reach.
Dynavax's innovative pipeline, including the shingles vaccine candidate Z-1018, will be amplified by Sanofi's resources.
The transaction addresses significant unmet public health needs in adult immunization for hepatitis B and shingles.

Negatives

Dynavax will cease to be an independent publicly traded company.
Potential for disruption to Dynavax's business and relationships with employees and business partners during the acquisition process.
The transaction is subject to various closing conditions, including regulatory approvals, which could delay or prevent consummation.

Risks

Risks related to the timing of the tender offer and the subsequent merger.
Uncertainty whether sufficient Dynavax stockholders will tender their shares in the tender offer.
The possibility that competing offers or acquisition proposals will be made.
The risk that various conditions to the consummation of the Offer or the Merger may not be satisfied or waived, including governmental entities prohibiting, delaying, or refusing approval.
Risks associated with acquisitions, such as disruption to Dynavax's business and difficulty in establishing or maintaining relationships with employees and business partners due to the announcement and pendency of the transactions.
Regulatory, manufacturing, or clinical effects from studies, FDA meetings, or adverse events could impact product candidates.
Market entry or threatened market entry of competitive products.
Manufacturing or supply chain disruptions.

Future Outlook

Sanofi expects the acquisition to augment its presence in adult immunization and bring new options to its portfolio. Dynavax believes joining Sanofi will provide global scale and expertise to maximize the impact of its vaccine portfolio, amplify opportunities for HEPLISAV-B and its innovative pipeline, and address important public health needs. The transaction is expected to close in the first quarter of 2026.

Management Comments

"Dynavax enhances Sanofi's adult immunization presence by adding differentiated vaccines that complement Sanofi's expertise. Its marketed adult hepatitis B vaccine and shingles candidate bring new options to our portfolio and underscore our commitment to providing vaccine protection across the lifespan." Thomas Triomphe, Executive Vice President, Vaccines, Sanofi.
"Joining Sanofi will provide the global scale and expertise needed to maximize the impact of our vaccine portfolio. We believe Sanofi's commercial reach, development capabilities and commitment to evidence-based immunization will amplify the opportunity for HEPLISAV-B and our innovative pipeline to address important public health needs, further advancing our mission to help protect the world against infectious disease. We are confident that this transaction – and the compelling value it provides – is in the best interests of the Company and its stockholders." Ryan Spencer, Chief Executive Officer, Dynavax.

Industry Context

The acquisition reflects a strategic move by Sanofi to strengthen its position in the adult immunization market, particularly in infectious diseases like hepatitis B and shingles. The focus on differentiated vaccines, such as HEPLISAV-B's two-dose regimen, indicates a trend towards more convenient and effective vaccination solutions. The emphasis on "unmet public health needs" for hepatitis B (100 million unvaccinated adults in the US) and shingles (1 in 3 adults affected) highlights the significant market potential and ongoing demand for innovative vaccine products. This aligns with broader pharmaceutical industry trends of consolidation and strategic acquisitions to expand portfolios and leverage global commercial infrastructures for specialized therapeutic areas.

Comparison to Industry Standards

HEPLISAV-B offers a differentiated two-dose regimen over one month, enabling high levels of seroprotection faster than other hepatitis B vaccines, which typically require three doses over six months. This accelerated regimen could provide a competitive advantage in the adult hepatitis B vaccine market.
The acquisition of a Phase 1/2 shingles vaccine candidate (Z-1018) positions Sanofi to potentially compete in the growing shingles vaccine market, currently dominated by products like GSK's Shingrix, which also targets adults. The filing does not provide specific comparative data for Z-1018 against existing market leaders, but its inclusion suggests a strategic intent to develop a competitive offering.
The premium paid (39% over closing, 46% over 3-month VWAP) is a strong indicator of Sanofi's valuation of Dynavax's assets and market position, often exceeding typical premiums in pharmaceutical acquisitions, reflecting the strategic value of the vaccine portfolio.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President and Chief Operating Officer	NA	David F. Novack	December 23, 2025	Will continue in role until earlier of Effective Time or Merger Agreement termination.
Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs	NA	Robert Janssen, M.D.	December 23, 2025	Will continue in role until earlier of Effective Time or Merger Agreement termination.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Bylaws Amendment	The bylaws of the Surviving Corporation will be amended and restated to conform to the form attached as Exhibit C, effective at the Effective Time.	Effective Time of Merger	Standard change for a wholly-owned subsidiary, aligning governance with parent company structure.
Certificate of Incorporation Amendment	The certificate of incorporation of the Surviving Corporation will be amended and restated to conform to the form attached as Exhibit B, effective at the Effective Time.	Effective Time of Merger	Standard change for a wholly-owned subsidiary, aligning governance with parent company structure.
Board of Directors Composition	The directors of the Surviving Corporation immediately after the Effective Time shall be the respective individuals who are the directors of Purchaser immediately prior to the Effective Time.	Effective Time of Merger	Ensures Sanofi's control over the acquired entity post-merger.
Officer Composition	The officers of the Surviving Corporation immediately after the Effective Time shall be the respective individuals who are the officers of Purchaser immediately prior to the Effective Time.	Effective Time of Merger	Ensures Sanofi's control over the acquired entity post-merger.
Section 203 DGCL Inapplicability	The Company Board has taken all actions to make the restrictions applicable to business combinations contained in Section 203 of the DGCL inapplicable to the execution, delivery, and performance of the Merger Agreement and the consummation of the Offer, Merger, and other Transactions.	Prior to Agreement Date	Removes potential anti-takeover hurdles, facilitating the acquisition.
Rule 14d-10 Matters	The Compensation Committee of the Company Board will approve, as an employment compensation, severance or other employee benefit arrangement within the meaning of Rule 14d-10(d)(2) under the Exchange Act, each agreement, arrangement or understanding between the Company or any of its Affiliates and any of the officers, directors or employees of the Company that are effective as of the Agreement Date pursuant to which compensation is paid to such officer, director or employee and will take all other action reasonably necessary to satisfy the requirements of the non-exclusive safe harbor set forth in Rule 14d-10(d)(2) under the Exchange Act.	Prior to Offer Acceptance Time	Ensures compliance with tender offer rules regarding executive compensation, preventing potential 'sweetheart deal' claims.

Legal Proceedings

The Company shall promptly notify Parent of any securityholder litigation brought against the Company and/or members of the Company Board or the Company's officers (in their respective capacities as such) relating to the Transactions.
The Company will control any such litigation but must allow Parent to review and comment on all material filings or responses and consult on settlements, with Parent's prior written consent required for settlement.

Stakeholder Impact

Shareholders: Will receive $15.50 per share in cash, representing a significant premium, providing immediate liquidity and a favorable return.
Employees: Current employees (Continuing Employees) will receive base salary, target annual cash incentive opportunities, and health, welfare, and retirement benefits no less favorable than prior to the Effective Time for at least one year. Service credit will be given for benefit eligibility and vesting. Certain unvested equity awards will convert to cash-based awards with deferred vesting.
Customers: HEPLISAV-B and other pipeline products will benefit from Sanofi's global scale and commercial reach, potentially expanding access and market penetration.
Management: Key management (President & COO, CMO & SVP) will continue in their roles until the merger's effective time.
Creditors (Convertible Note Holders): The Company will take actions in accordance with Convertible Notes Indentures, which may involve repurchases or conversions triggered by the merger.

Next Steps

Sanofi will commence a cash tender offer no later than ten business days after the Agreement Date (December 23, 2025).
Dynavax will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
Purchaser will merge with and into Dynavax as soon as practicable following the consummation of the Offer.
The transaction is expected to close in the first quarter of 2026.
Dynavax will cooperate with Parent to delist shares from Nasdaq and deregister under the Exchange Act after the Effective Time.
Dynavax will take actions to address Convertible Notes and Capped Call Transactions in accordance with their terms.

Key Dates

Date	Description
2023-01-01	Start date for compliance with various laws and regulations, and absence of certain legal proceedings or adverse findings.
2024-01-01	Start date for timely SEC filings, maintenance of internal controls, and compliance with applicable laws.
2025-01-24	Date of the initial Confidentiality Agreement between Dynavax and Sanofi Pasteur Inc.
2025-03-13	Date of the indenture for the 2.00% Convertible Senior Notes due 2030.
2025-05-10	Date of letter agreements related to call options on Company Common Stock (Capped Call Documentation).
2025-05-13	Date of the indenture for the 2.50% Convertible Senior Notes due 2026.
2025-12-05	Date of Amendment No. 1 to the Confidentiality Agreement between Dynavax and Sanofi Pasteur Inc.
2025-12-23	Date of the Agreement and Plan of Merger; Date of earliest event reported; Dynavax's closing share price reference date for premium calculation; Dynavax Board determined David F. Novack and Robert Janssen, M.D. would continue in their roles.
2025-12-24	Date Dynavax issued a press release announcing the execution of the Merger Agreement.
2025-12-29	Date the 8-K report was signed by Kelly MacDonald, Senior Vice President, CFO.
2026-06-23	Initial End Date for the consummation of the Offer and Merger, extendable twice by 90 days each.
2026-09-21	First potential extended End Date if regulatory conditions are outstanding.
2026-12-20	Second potential extended End Date if regulatory conditions are outstanding.

Recommendation

strong buy

The acquisition offers a substantial premium of 39% over the recent closing price and 46% over the 3-month VWAP, providing a compelling and immediate cash return for Dynavax shareholders. The unanimous board approval further reinforces the attractiveness of the offer. For investors, this represents a clear opportunity for a significant, near-term gain by tendering shares.

Keywords

Dynavax, Sanofi, Acquisition, Merger, HEPLISAV-B, Hepatitis B Vaccine, Shingles Vaccine, Z-1018, Vaccines, Biopharmaceutical, Tender Offer, Adult Immunization, DVAX, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.